ClinicalTrials.gg
Active, not recruitingNCT06008093TRITONUpdated Nov 2, 2026

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

A Phase 2 interventional study of Durvalumab and Tremelimumab in Carcinoma, Non-Small-Cell Lung, sponsored by AstraZeneca. Active, not recruiting at 47 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
34th of 94
103 · median 74
Started
2024
with 7 others
Phase 2
58 of 94
11 open now
Primary completion
2026-10
later than 20 of 36 live
Registered
83rd of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 34th largest by enrollment, is one of 8 that started in 2024, is one of 58 in phase 2, reaches primary completion later than 20 of the 36 other live ones, and was the 83rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.

Read the detailed description

A trial to learn if durvalumab plus tremelimumab with chemotherapy is safe and how well it works compared to pembrolizumab with chemotherapy in participants with metastatic non-small cell lung cancer with certain genetic mutations.

INFORMATION FOR TRIAL PARTICIPANTS:

Researchers are looking for a better way to treat people who have metastatic NSCLC and tumors with STK11, KEAP1, or KRAS genetic mutations. Most people learn they have NSCLC after it has already become metastatic, and it can no longer be treated with surgery.

Based on previous trials, researchers think durvalumab plus tremelimumab with chemotherapy could help participants more than the current standard treatment, which is pembrolizumab with chemotherapy. Durvalumab and tremelimumab are designed to work by helping the immune system recognize and kill cancer cells.

In this trial, researchers want to learn more about how well durvalumab plus tremelimumab with chemotherapy works in people with metastatic NSCLC and genetic mutations that can cause the cancer to be less responsive to treatment.

This trial is planned to have 100 participants. These participants will be randomly divided into one of two groups:

  • One group will receive durvalumab plus tremelimumab with standard of care chemotherapy
  • One group will receive pembrolizumab with standard of care chemotherapy

Durvalumab, tremelimumab, pembrolizumab, and chemotherapy are given as an injection over time into a vein, also called an IV infusion. Chemotherapy will be one of the following regimens: pemetrexed plus cisplatin or pemetrexed plus carboplatin.

This is an open-label trial. This means that each participant will know which trial treatment they receive, and the doctors and trial staff will also know.

Researchers will measure and compare:

  • How long participants live during the trial without their cancer getting worse
  • How long participants live during the trial
  • How many participants' tumors respond to treatment
  • How long participants' tumor responses last
  • How long before participants need to start a different treatment type

Researchers will also keep track of all the medical problems participants have during the trial and monitor their safety.

Participants will stop receiving trial treatment if they no longer benefit from it, at trial close, or if they stop participating for another reason.

Participants will visit their trial site every 3 to 4 weeks. At most visits, participants will:

  • Have a physical exam and answer questions about any medications they are taking or any medical problems they have
  • Receive their trial treatment
  • Give blood and urine samples
  • Have pictures of their tumors taken using CT or MRI scans
03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Mutation
  • Metastatic Non-Small Cell Lung Cancer
  • Kelch-Like ECH-Associated Protein 1 (KEAP1)
  • Kirsten rat sarcoma virus (KRAS)
  • Programmed death-ligand 1 (PD-L1)
  • Serine/threonine kinase 11 (STK11)
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented Stage IV non-squamous NSCLC not amenable to curative surgery or radiation.
  • Participants must have tumors with STK11 or KEAP1 or KRAS mutations. Co-mutations are also allowed.
  • Participants must have tumors that lack activating epidermal growth factor receptor mutations and ALK fusions.
  • No prior chemotherapy or any other systemic therapy for NSCLC. Participants who have received prior platinum-containing adjuvant, , or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred > 6 months from end of last therapy.
  • No prior exposure to immune-mediated therapy excluding therapeutic anti-cancer vaccines, within 6 months of randomization.
  • performance status of 0 or 1 at enrollment and randomization.
  • Minimum ≥ 12 weeks at randomization.
  • At least 1 lesion, not previously irradiated, that qualifies as a 1.1 target lesion at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter with Computed Tomography (CT)/CT- Positron Emission Tomography or Magnetic Resonance Imaging and that is suitable for accurate repeated measurements as per RECIST 1.1 guidelines.
  • Adequate organ and bone marrow function.
  • Negative pregnancy test (urine or serum) for women of
  • Female participants must be 1 year , surgically sterile, or using one highly effective form of
  • Male and Female participants and their partners must use an acceptable method of contraception.
  • Body weight of > 30 kg

Exclusion criteria

Exclusion Criteria:

  • Any evidence of acute or uncontrolled diseases or history of allogeneic organ transplant.
  • Mixed small cell lung cancer and NSCLC histology.
  • Major surgical procedure within 28 days prior to the first dose of the study intervention or an anticipated need for major surgery during the study.
  • Active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], systemic lupus erythematosus, sarcoidosis, granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis [requiring systemic therapy, eg, methotrexate, ], hypophysitis, uveitis, etc), autoimmune pneumonitis and autoimmune myocarditis. The following are exceptions to this criterion:

    • Participants with vitiligo or alopecia.
    • Participants with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement.
    • Any chronic skin condition that does not require systemic therapy.
    • Participants without active disease in the last 5 years may be included but only after consultation with the Study Clinical Lead.
    • Participants with celiac disease controlled by diet alone.
  • Medical to platinum-based doublet chemotherapy.
  • History of another primary except:

    • Malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence
    • Adequately resected non-melanoma skin cancer and curatively treated in situ disease.
  • Persistent toxicities ( [CTCAE] Grade ≥ 2) caused by previous anti-cancer therapy, alopecia and vitiligo are excluded toxicities.
  • Participants with Grade ≤ 2 neuropathy can be considered based on Investigator's judgement. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by treatment with study intervention in the opinion of the Investigator may be included (eg, hearing loss).
  • Spinal cord compression unless asymptomatic and stable.
  • Participant meets the following:

    - Symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which requires treatment (CTCAE Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted based on the Investigator judgement with cardiologist consultation recommended.

  • Any concurrent chemotherapy, product, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable.
  • No radiation therapy is allowed, unless it is 1) definitive radiation that had been administered at least 6 months prior, 2) palliative radiation to brain, with associated criteria for stability or lack of symptoms, or 3) palliative radiation to painful bony lesions (this must comprise less than 30% of the bone marrow)
  • Patients with suspected at screening should have an IV contrast-enhanced MRI (preferred) or IV contrast-enhanced CT/CT-PET of the brain prior to study entry. If brain metastases are detected patients must be treated before randomization. Randomization is only permitted if patients with brain metastases have:

    • Confirmed stable condition
    • Returned neurologically to baseline Brain metastases will not be recorded as target lesions at baseline.
  • History of .
  • Known to have tested positive for active tuberculosis infection
  • Known active hepatitis infection, positive antibody, , or anti-HBc, at screening. Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if PCR is negative for HCV RNA. Participants co-infected with HBV and HCV, or co-infected with HBV and HDV, namely: HBV positive (presence of HBsAg and/or anti-HBcAb with detectable HBV DNA); AND

    • HCV positive (presence of anti-HCV antibodies); OR
    • HDV positive (presence of anti-HDV antibodies).
  • Known (HIV) infection that is not well controlled.
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of study intervention. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids or local steroid injections (eg, intra-articular injection).
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent.
    • Steroids as premedication for reactions (eg, CT scan premedication, premedication for chemotherapy) or a single dose for palliative purpose (eg, pain control).
  • Receipt of within 30 days prior to the first dose of study intervention.
  • Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study.
  • Participants with a known hypersensitivity to any of the study interventions or any of the of the products.
  • For females only: Currently pregnant (confirmed with positive pregnancy test) or breastfeeding, or who are planning to become pregnant.

Female participants should refrain from breastfeeding from enrolment throughout the study and until up to 14 months after the last dose of cisplatin or 180 days after pemetrexed or 90 days after tremelimumab or durvalumab or pembrolizumab, whichever is longer; and during treatment with carboplatin.

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy

    Participants will receive durvalumab plus tremelimumab every 3 weeks (q3w) for four 21-day cycles in combination with chemotherapy followed by maintenance treatment period (durvalumab plus pemetrexed maintenance) every 4 weeks (q4w) until clinical progression or confirmed RECIST 1.1- defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of participant consent, or EOS, whichever comes first. During the maintenance treatment period, participants will receive additional doses of tremelimumab at Cycle 6 (Week 16) and Cycle 28 (Week 104 - at Investigator's discretion) along with durvalumab and pemetrexed.

    Drug: Durvalumab · Drug: Tremelimumab · Drug: Pemetrexed · Drug: Carboplatin · Drug: Cisplatin

  • Experimental
    Arm B: Pembrolizumab + Platinum-based Chemotherapy

    Participants will receive pembrolizumab regimen q3w for four 21-day cycles in combination with chemotherapy as induction treatment followed by maintenance treatment (pembrolizumab plus pemetrexed maintenance) q3w for up to 24 months, until clinical progression or confirmed RECIST 1.1- defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of participant consent, or EOS, whichever comes first.

    Drug: Pemetrexed · Drug: Pembrolizumab · Drug: Carboplatin · Drug: Cisplatin

Interventions

  • Participants will receive intravenous (IV) Durvalumab q3w for four 21-day cycles as induction treatment. Durvalumab will also be given during the maintenance treatment period q4w until clinical progression or confirmed RECIST 1.1- defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of participant consent, or EOS, whichever comes first.

    Also known as: MEDI4736 & IMFINZI®

  • Participants will receive IV Tremelimumab q3w for four 21-days cycles as induction treatment. Tremelimumab will also be given during the maintenance therapy phase at week 16 and week 104 (at the investigators discretion).

    Also known as: IMJUDO®

  • Participants in Arm A and Arm B will receive IV pemetrexed q3w for four 21-day cycles as induction treatment. In the maintenance therapy phase, Treatment Arm A will receive Pemetrexed q4w, Treatment Arm B will receive Pemetrexed q3w until clinical progression or confirmed RECIST 1.1- defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of participant consent, or EOS, whichever comes first.

    Also known as: Background Platinum-based Chemotherapy

  • Participants will receive IV pembrolizumab q3w for four 21-days cycles as induction treatment. Pembrolizumab will also be given in the maintenance treatment phase q3w until clinical progression or confirmed RECIST 1.1- defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of participant consent, or EOS, whichever comes first.

  • Participants will receive IV Carboplatin or IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles as induction treatment.

    Also known as: Background Platinum-based Chemotherapy

  • Participants will receive IV Carboplatin or IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles as induction treatment.

    Also known as: Background Platinum-based Chemotherapy

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) in randomized participants

    PFS is defined as the time from randomization until the date of confirmed PD (per Response Evaluation Criteria in Solid Tumours, Version 1.1 \[RECIST 1.1\] as assessed by the Investigator) or death due to any cause. The measure of interest is the hazard ratio (HR) and the corresponding 95% confidence interval (CI).

    Time frame: From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)

  2. PFS at 6 months

    PFS is defined as the time from randomization until the date of confirmed PD (per RECIST 1.1 as assessed by the Investigator) or death due to any cause. The measure of interest is the PFS rate and the corresponding 95% CI at 6 months.

    Time frame: From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)

  3. PFS at 12 months

    PFS is defined as the time from randomization until the date of confirmed PD (per RECIST 1.1 as assessed by the Investigator) or death due to any cause. The measure of interest is the PFS rate and the corresponding 95% CI at 12 months.

    Time frame: From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)

Secondary outcomes

  1. Overall survival (OS) at 12 months

    OS is defined as the time from randomization until death due to any cause. The measure of interest is the OS rate with corresponding 95% CI at 12 months landmark.

    Time frame: At 12 months

  2. OS at 24 months

    OS is defined as the time from randomization until death due to any cause. The measure of interest is the OS rate with corresponding 95% CI at 24 months landmark.

    Time frame: At 24 months

  3. OS at 12 months in subset of randomized participants with STK11, KEAP1 or KRAS mutation and/or co mutations

    OS is defined as the time from randomization until death due to any cause. The measure of interest is the OS rate with corresponding 95% CI at 12 months landmark.

    Time frame: At 12 months

  4. OS at 24 months in subset of randomized participants with STK11, KEAP1 or KRAS mutation and/or co mutations

    OS is defined as the time from randomization until death due to any cause. The measure of interest is the OS rate with corresponding 95% CI at 24 months landmark.

    Time frame: At 24 months

  5. OS in randomized participants

    OS is defined as the time from randomization until death due to any cause. The measure of interest is the HR with corresponding 95% CI.

    Time frame: From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)

  6. Objective response rate (ORR)

    ORR is defined as the proportion of participants with a confirmed objective tumour response (complete response \[CR\] or partial response \[PR\]) per RECIST 1.1, as assessed by the Investigator. The measures of interest is common risk difference with corresponding 95% CI.

    Time frame: From randomization until disease progression, or the last evaluable assessment in the absence of progression (approximately 48 months)

  7. Duration of response (DOR)

    DOR is defined as the time from the date of first documented confirmed response until the date of documented progression (per RECIST 1.1, as assessed by the Investigator) or death due to any cause in all randomized participants as randomized (FAS) who have confirmed objective response. The measure of interest is the median duration of response and the corresponding 95% CI.

    Time frame: From first documented response until documented progression (approximately 48 months)

  8. Time to First Subsequent Therapy (TFST)

    TFST is defined as the time from randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized intervention, or death due to any cause. The measure of interest is the median TFST and the corresponding 95% CI.

    Time frame: From randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized study intervention or death (approximately 48 months)

  9. Number of participants with adverse events (AEs)

    To assess the safety and tolerability of durvalumab plus tremelimumab plus chemotherapy compared with pembrolizumab plus chemotherapy in participants with non-squamous histology who have metastatic NSCLC with mutations and/or co-mutations in STK11, KEAP1, or KRAS.

    Time frame: From screening until the follow-up period is completed (approximately 48 months)

07

Study locations

47 sites
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Los Alamitos, California 90720, United States
  • Research Site
    Los Angeles, California 90034, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Fort Lauderdale, Florida 33308, United States
  • Research Site
    Jupiter, Florida 33458, United States
  • Research Site
    Ocala, Florida 34474, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    Atlanta, Georgia 30318, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Honolulu, Hawaii 96813, United States
  • Research Site
    Carterville, Illinois 62918, United States
  • Research Site
    Urbana, Illinois 61801, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Jamaica Plain, Massachusetts 02130, United States
  • Research Site
    Saint Paul, Minnesota 55101, United States
  • Research Site
    Kansas City, Missouri 64132, United States
  • Research Site
    St Louis, Missouri 63128, United States
  • Research Site
    Billings, Montana 59102, United States
  • Research Site
    Grand Island, Nebraska 68803, United States
  • Research Site
    Lincoln, Nebraska 68506, United States
  • Research Site
    Albany, New York 12206, United States
  • Research Site
    East Syracuse, New York 13057, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Shirley, New York 11967, United States
  • Research Site
    Stony Brook, New York 11790, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    The Bronx, New York 10461, United States
  • Research Site
    Cleveland, Ohio 44111, United States
  • Research Site
    Cleveland, Ohio 44124, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Dayton, Ohio 45459, United States
  • Research Site
    Norman, Oklahoma 73072, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Denton, Texas 76210, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Kingwood, Texas 77339, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Richmond, Virginia 23298, United States
08

References and documents

Publications

  • Skoulidis F, Borghaei H, Garon EB, Leal TA, Kaufman J, Liu SV, Nadler E, Patel SP, Peters S, Ricciuti B, Gautam A, Emeribe U, Luciani-Silverman L, Heymach JV. Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study. Ther Adv Med Oncol. 2025 Nov 6;17:17588359251386611. doi: 10.1177/17588359251386611. eCollection 2025. PubMed 41209621 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Oct 2026, 30 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 30 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Completion moved once since we started tracking on Sep 25, 2026: Feb 2028 → Jan 2028, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Aug 23, 2023
StartActual
Apr 4, 2024
Primary completionEst.
Oct 27, 2026
CompletionEst.
Jan 5, 2028was Feb 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 23, 2026→Oct 27, 2026
Nov 2, 2026
Study completion
Feb 28, 2028→Jan 5, 2028
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Oct 23, 2026→Oct 27, 2026
    Study completion Feb 28, 2028→Jan 5, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06008093
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Apr 4, 2024
Primary completion
Oct 27, 2026 (estimated)
Completion
Jan 5, 2028 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion